Benjamin Liu argues that drug development and clinical trials can constrain the number of discovered candidates that reach patients. He describes a $600 million fund intended to license and develop individual drug candidates alongside Formation Bio’s team.
Liu explains the company’s claimed uses of AI to assess drug targetsAI-assisted scientific discovery uses AI to support hypothesis generation, experiment design, analysis, simulation, literature work, and interpretation while researchers retain responsibility., match them with diseases and support study design. He stresses the role of expert judgmentHuman-in-the-loop AI keeps a person involved in reviewing, correcting, approving, or guiding an AI system's work. and says some safety studies and trial endpoints cannot simply be compressed.
He discusses financing and portfolio trade-offs and potential areas of interest, including joint health and neurological conditions. These are the company’s plans and expectations; candidate medicines still require clinical testing for safety and efficacyExperimental validation tests a prediction or proposed mechanism with measured observations from a suitable real-world or laboratory experiment..
Watch on YouTube
